Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Chief Legal Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 841,640 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 221,100 · Balance 841,640 F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANTARES PHARMA, INC.
Report date May 24, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-24 · Disposition to issuer · Disposed 414,470 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-24 · Disposition to issuer · Disposed 202,139 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-05-24 · Disposition to issuer · Disposed 124,234 · Balance 0 F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-24 · Disposition to issuer · Disposed 125,000 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-24 · Disposition to issuer · Disposed 212,900 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.66 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-24 · Disposition to issuer · Disposed 217,725 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-24 · Disposition to issuer · Disposed 177,453 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-24 · Disposition to issuer · Disposed 170,227 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-24 · Disposition to issuer · Disposed 254,165 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-24 · Disposition to issuer · Disposed 163,963 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 21:16 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 221,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-047034 · wk-form4_1783026998.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 841,640 F1 · shares: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:43 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 33,294 | $3.99 | $132,843.06 |
DisclosureSEC source: 0001628280-26-009280 · wk-form4_1771454589.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,540 F2 · shares: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:43 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 294,800 | $3.99 | $1,176,252.00 |
DisclosureSEC source: 0001628280-26-009280 · wk-form4_1771454589.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653,834 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2025 Filed Dec 9, 2025 22:09 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 49,508 | $3.29 | $162,881.32 |
DisclosureSEC source: 0001628280-25-056169 · wk-form4_1765318168.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,034 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:23 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 220,000 | $1.61 | $354,200.00 |
DisclosureSEC source: 0001628280-25-005863 · wk-form4_1739575395.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,542 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 01:35 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 41,458 | $3.13 | $129,763.54 |
DisclosureSEC source: 0001628280-24-050540 · wk-form4_1733794514.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,542 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 163,963 | Not disclosed Strike: $4.42 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 10 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,963 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 254,165 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 9 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 254,165 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 170,227 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 8 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,227 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 177,453 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 7 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 177,453 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 217,725 | Not disclosed Strike: $2.66 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 6 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 217,725 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 212,900 | Not disclosed Strike: $1.12 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 5 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 212,900 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerStock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $2.29 | Not disclosed |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · derivative · entry 4 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires not disclosed F5 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F5 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerCommon Stock | 124,234 | $5.60 | $695,710.40 |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · nonDerivative · entry 3 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · security: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerCommon Stock | 202,139 | $5.60 | $1,131,978.40 |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:25 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Disposition to issuerCommon Stock | 414,470 | $5.60 | $2,321,032.00 |
DisclosureSEC source: 0000899243-22-019789 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 18:34 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 13,635 | $3.80 | $51,813.00 |
DisclosureSEC source: 0001016169-22-000031 · wf-form4_164643687992101.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,609 Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 18:34 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 26,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001016169-22-000031 · wf-form4_164643687992101.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,244 F1 · security: On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 19:19 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 13,299 | $3.66 | $48,674.34 |
DisclosureSEC source: 0001016169-22-000016 · wf-form4_164522993007298.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,200 F1 · security: On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 19:19 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 23,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001016169-22-000016 · wf-form4_164522993007298.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,499 F1 · security: On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| June 13, 2021 Filed Jun 14, 2021 18:21 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 14,790 | $4.45 | $65,815.50 |
DisclosureSEC source: 0001209191-21-040328 · doc4.xml · nonDerivative · entry 3 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,431 F2 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F2 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 18:21 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 23,010 | $4.45 | $102,394.50 |
DisclosureSEC source: 0001209191-21-040328 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,221 F2 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F2 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:21 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 163,963 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-21-040328 · doc4.xml · derivative · entry 4 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,963 Underlying: Common Stock · 163,963 shares Expires 2031-06-10 F3 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F4 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:21 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 85,973 | $4.42 | $380,000.66 |
DisclosureSEC source: 0001209191-21-040328 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,231 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:38 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 15,996 | $4.39 | $70,222.44 |
DisclosureSEC source: 0001209191-21-039591 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,258 F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:32 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 23,992 | $4.50 | $107,964.00 |
DisclosureSEC source: 0001209191-21-017266 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,254 F1 · kind: On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:32 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 45,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017266 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,246 F1 · kind: On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · derivative · entry 6 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of June 2, 2016. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | SaleCommon Stock | 5,000 | $5.05 | $25,250.00 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · nonDerivative · entry 5 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,417 F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | SaleCommon Stock | 40,000 | $4.91 | $196,400.00 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · nonDerivative · entry 4 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,417 F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Exercise / conversionCommon Stock | 45,000 | $1.12 | $50,400.00 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · nonDerivative · entry 3 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 42,073 | $4.73 | $199,005.29 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,417 F1 · kind: On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 19:07 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 80,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012543 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,490 F1 · kind: On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold. Read SEC document |
| June 13, 2020 Filed Jun 15, 2020 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 15,036 | $2.78 | $41,800.08 |
DisclosureSEC source: 0001209191-20-036778 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,125 F2 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 254,165 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-20-036778 · doc4.xml · derivative · entry 3 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,165 Underlying: Common Stock · 254,165 shares Expires 2030-06-11 F3 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F4 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 131,868 | $2.73 | $359,999.64 |
DisclosureSEC source: 0001209191-20-036778 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,161 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 18:30 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 16,261 | $3.13 | $50,896.93 |
DisclosureSEC source: 0001209191-20-035382 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,293 F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 07, 2020 Filed Jun 9, 2020 18:30 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 17,994 | $3.12 | $56,141.28 |
DisclosureSEC source: 0001209191-20-035382 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,554 F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:28 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 29,947 | $3.53 | $105,712.91 |
DisclosureSEC source: 0001209191-20-011721 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,548 F1 · kind: On August 25, 2017, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:28 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 63,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011721 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,495 F1 · kind: On August 25, 2017, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:32 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 170,227 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001209191-19-037213 · doc4.xml · derivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,227 Underlying: Common Stock · 170,227 shares Expires 2029-06-13 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:32 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 84,760 | $2.92 | $247,499.20 |
DisclosureSEC source: 0001209191-19-037213 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,261 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. Read SEC document |
| June 08, 2019 Filed Jun 11, 2019 17:43 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 11,678 | $2.81 | $32,815.18 |
DisclosureSEC source: 0001209191-19-036147 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,501 F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 17:43 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 12,922 | $2.81 | $36,310.82 |
DisclosureSEC source: 0001209191-19-036147 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,179 F1 · kind: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · shares: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. F1 · acquired: Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold. Read SEC document |
| June 02, 2019 Filed Jun 4, 2019 17:13 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 15,421 | $2.79 | $43,024.59 |
DisclosureSEC source: 0001209191-19-034411 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,101 F1 · kind: Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award. F1 · shares: Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award. F1 · acquired: Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:47 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 32,386 | $3.20 | $103,635.20 |
DisclosureSEC source: 0001209191-19-012777 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,522 F1 · kind: On June 2, 2016, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:47 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 84,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012777 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,908 F1 · kind: On June 2, 2016, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 177,453 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-18-037103 · doc4.xml · derivative · entry 3 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,453 Underlying: Common Stock · 177,453 shares Expires 2028-06-08 F3 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. F4 · derivative.exercise_date: The options vest in equal quarterly installments over three years from the date of grant. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 91,667 | $2.70 | $247,500.90 |
DisclosureSEC source: 0001209191-18-037103 · doc4.xml · nonDerivative · entry 2 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,173 F2 · shares: Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 19:09 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 12,923 | $2.70 | $34,892.10 |
DisclosureSEC source: 0001209191-18-037103 · doc4.xml · nonDerivative · entry 1 GRAHAM PETER J · CIK 0001235635 · EVP General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,506 F1 · shares: Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.